Esperion Presents CLEAR Outcomes Analysis of Inflammation as Predictor of Cardiovascular Risk at American Heart Association Scientific Sessions 2023
13. November 2023 10:30 ET
|
Esperion Therapeutics, Inc.
– A Prespecified, Exploratory Analysis of Participants Reports Those with Higher Baseline Inflammation More Likely to Experience a Major Cardiovascular Event (MACE), Cardiovascular Death, and...
Partners Announce TRANSFORM Trial to Evaluate Personalized Heart Disease Care Strategies at American Heart Association 2023
11. November 2023 11:00 ET
|
Esperion Therapeutics, Inc.
– Data from Randomized Control Trial Will Advance Evidence for Evaluation and Treatment of Heart Disease by Studying Actual Disease: Atherosclerosis – ANN ARBOR, Mich., Nov. 11, 2023 (GLOBE...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
09. November 2023 16:30 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 8, 2023, the Company granted 18 new employees 141,800 restricted stock units (RSUs)...
Esperion Reports Third Quarter 2023 Financial Results
07. November 2023 06:00 ET
|
Esperion Therapeutics, Inc.
– Q3 U.S. Net Product Revenue Grew 45% Y/Y to $20.3 Million; Q3 Total Revenue Grew 79% Y/Y to $34.0 Million – – Q3 Retail Prescription Equivalents Grew 33% Y/Y and 8% Q/Q, Demonstrating Sustained...
Esperion to Participate in Jefferies London Healthcare Conference
31. Oktober 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the Jefferies London Healthcare Conference. Sheldon Koenig, President and Chief...
Esperion to Report Third Quarter 2023 Financial Results on November 7
24. Oktober 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report third quarter 2023 financial results before the market opens on Tuesday, November 7, 2023....
American College of Cardiology Program to Increase Cholesterol Screenings
12. September 2023 10:15 ET
|
Esperion Therapeutics, Inc.; The American College of Cardiology
Quality Improvement and Education Program sponsored by Amgen, Esperion to improve adherence to guideline recommendations for managing LDL WASHINGTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The American...
Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference
28. August 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig,...
Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023
26. August 2023 11:00 ET
|
Esperion Therapeutics, Inc.
– In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 – – In an analysis of patients with diabetes, bempedoic acid shows 17%...
Two CLEAR Outcomes Study Late-Breakers Accepted at European Society of Cardiology (ESC) Congress 2023
11. August 2023 08:00 ET
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced two oral presentations to take place in the Late-Breaking Science Session entitled “Clinical trial updates...